Melatonina
Anno: 2002
-
Riferimento:Cancer Lett 2002 May 28;179(2):141-50.Azione della melatonina:Melatonin and the mt1 and MT2 agonist, but not RORalpha agonist, can repress RORalpha transcriptional activity in MCF-7 cells.Target:Retinoic orphan receptor alpha (RORalpha)
-
Riferimento:Neuro Endocrinol Lett. 2002 Jul;23 Suppl 2:17-22.Azione della melatonina:Less than 1 lux of monochromatic light, between 446-484 nm, elicited a significant suppression of nocturnal melatonin.Target:LAN
-
Riferimento:Environ Health Perspect. 2002 Feb;110(2):A72-3.Azione della melatonina:No abstract availableTarget:No abstract available
-
Riferimento:Med Hypotheses. 2002 Jul;59(1):39-51.Azione della melatonina:Elevated magnetic field exposures associated with breast and other cancers has been postulated via modified melatonin activity.Target:ELF
-
Riferimento:Am J Epidemiol. 2002 Mar 1;155(5):446-54.Azione della melatonina:These data do not support the hypothesis that exposure to residential magnetic fields (60-Hz) is associated with an increased risk of breast cancer.Target:ELF
-
Riferimento:Pol J Pathol. 2002;53(2):59-65.Azione della melatonina:Retinoids induce the apoptotic pathway in a dose-dependent manner, melatonin (10(-5) M) added to the culture enhances this effect.Target:Estrogen sensitive (ER+)
-
Riferimento:Breast Cancer Res Treat. 2002 Jan;71(1):37-45.Azione della melatonina:Melatonin pre-treatment ((10(-9)-10(-6) M) for 30 min) significantly reduced E2-induced ERalpha transactivation and Eralpha-ERE(estrogen response element) binding activity.Target:Estrogen receptor-alpha (ERalpha)
-
Riferimento:Mol Cell Endocrinol. 2002 Jun 28;192(1-2):147-56.Azione della melatonina:Involvement of the MT(1) melatonin receptor in mediation of melatonin effects on growth-suppression and gene-modulation in breast cancer cells.Target:MT(1) receptor
-
Riferimento:Epidemiology. 2002 Jan;13(1):116.Azione della melatonina:No abstract available.Target:No abstract available.
Anno: 2003
-
Riferimento:J Surg Res. 2003 Apr;110(2):332-7.Azione della melatonina:Combination therapy with 1,25-(OH)(2)-D(3) and MEL in the treatment of breast cancer suggest that the growth inhibition could be related to the enhanced TGF-beta(1) secretion.Target:Dihydroxyvitamin D(3) Transforming growth-factor beta 1